Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acne Vulgaris: full-pipeline trial registry
2 of 68 indexed Acne Vulgaris trials are currently recruiting.
Corpus placement: #203 of 28,707 conditions by registered trial count.
68 US clinical trials · 2 currently recruiting · #203 of 28,707 conditions by registered trial count
Acne Vulgaris: 68 US clinical trials tracked, 2 recruiting.
Acne Vulgaris is the subject of 68 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is Galderma R&D, running 7 of these trials.
Enrollment posture brief
Registry condition acne-vulgaris
OPEN 2 | RECR 3% | LATE 26 | EARLY 33 | RANK #203 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Coronary Disease (3% recruiting · 36 trials)
Acne Vulgaris lists 2 open slots (3% of 68 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acne Vulgaris on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acne Vulgaris is recruiting below its size-band peers.
2 of 68 indexed trials (2.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acne Vulgaris trials is spread across many organizations.
Galderma R&D accounts for 7 of 68 trials (10.3%). 38 distinct sponsors appear on at least one study for this condition label.
-
Typical Acne Vulgaris enrolment sits around 126 participants.
Median target enrolment is 126 among the 68 trials that report a genuine target (sentinel values excluded). 30 of those (44.1%) plan for fewer than 100 participants.
-
Acne Vulgaris research is mostly interventional.
66 interventional and 2 observational studies make up this index (97.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
68 total, page 2 of 2
Infrared Non-Cutting Laser Therapy for Acne
University of Michigan
NCT00110643
A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin
Kenvue Brands
NCT07224633
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
Johnson & Johnson Consumer Inc. (J&JCI)
NCT03128723
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
Stiefel, a GSK Company
NCT01115322
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
Stiefel, a GSK Company
NCT01015638
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
Galderma R&D
NCT01209949
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
Massachusetts General Hospital
NCT00722761
A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Stiefel, a GSK Company
NCT01019603
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
Cassiopea SpA
NCT02720627
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
Bausch Health Americas
NCT01313728
Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
Bausch Health Americas
NCT00919191
Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris
Wake Forest University
NCT01047189
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Derm Research, P
NCT03402893
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Photocure
NCT00673933
Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Icahn School of Medicine at Mount Sinai
NCT03681470
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
Northwestern University
NCT00558831
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Naked Biome
NCT03450369
Timolol for the Treatment of Acne and Rosacea
Johns Hopkins University
NCT02774590
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 20 |
| Phase 3 | 12 |
| Phase 4 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Acne Vulgaris records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acne Vulgaris trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acne Vulgaris page
68 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Acne Vulgaris trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Galderma R&D sponsors the most Acne Vulgaris trials on record, review their full trial history before evaluating a specific study. See Galderma R&D's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acne Vulgaris condition card totals 68 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.